Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards (OnkoBot)

9 de novembro de 2026 atualizado por: Lisa Adams, Technical University of Munich

OnkoBot: Prospective Shadow-Mode Evaluation of a Locally Operated, Source-Grounded Large Language Model System for Drafting Multidisciplinary Tumor Board Recommendations

This study tests whether an artificial intelligence (AI) system that drafts tumor board recommendations performs as well on new cases as it did on archived cases. The system runs in shadow mode at three multidisciplinary tumor boards of TUM University Hospital rechts der Isar. For each case it drafts a recommendation before the board meets. The board does not see the draft, and the draft has no influence on patient care. After the meeting, each draft is compared with the board decision. The agreement rate is then compared with the rate measured on archived decisions of the same boards.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The system is a locally operated large language model (LLM) pipeline with retrieval-augmented generation. Its input is the case as presented to the board, with diagnosis, course, question and all patient documents dated before the board date. It retrieves guideline recommendations (Onkopedia and AWMF S3 guidelines in the version in force on the board date), laboratory values, precedent cases from the board archive and PubMed abstracts published before the board date. It then drafts a recommendation with justification. Each statement of the draft is linked to a verbatim quote from its source. All models run on local GPU servers of the hospital with no data retention beyond the immediate analysis, and no patient data are sent to external providers.

The study includes the hematology board, the orthopedics and sarcoma board and the head and neck board. For each case registered for a session, the system drafts a recommendation after the pre-board documents are pulled and before the session starts. Board members do not see the drafts. The decision pipeline (generator Gemma-4-31B at temperature 0) is frozen and versioned for the study period. The study uses routine clinical data only. Patients are not contacted, and no study-specific procedures are performed.

The draft is compared with the consensus decision in the board report. An LLM judge (GLM-5.3-Flash, majority of three votes) assigns both texts to one of seven decision categories: systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care and referral to the molecular tumor board. It also scores agreement in substance from 0 to 3 and records the direction of any disagreement. The judge was validated against clinician ratings on a sealed test set. The same prompt version is used to score the prospective cases and the retrospective reference sample, separately from any output that clinicians see.

The retrospective reference is the evaluation sample of archived decisions of the same three boards (about 2,000 cases, one per patient, drawn with a fixed seed and stratified by time). Patients who also appear in the prospective cohort are removed from the reference. The primary analysis tests non-inferiority of the prospective category match rate against the retrospective rate, pooled over the three boards, with a margin of 7.5 percentage points and a one-sided alpha of 0.025. The variance is cluster-robust for board sessions. A case without a draft counts as not concordant. Per-board results are reported descriptively with 95% confidence intervals. An exploratory component evaluates a trial-matching engine that proposes recruiting clinical trials per case.

In a subset of 30 to 50 cases per board, physicians rate the system draft against the board decision. This subset tests whether the agreement between judge and clinicians, measured retrospectively, also holds prospectively.

Tipo de estudo

Observacional

Inscrição (Estimado)

450

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Lisa Adams, MD
  • Número de telefone: +49 89 4150 1084
  • E-mail: lisa.adams@tum.de

Estude backup de contato

Locais de estudo

    • Bavaria
      • Munich, Bavaria, Alemanha, 81675
        • Ainda não está recrutando
        • TUM University Hospital rechts der Isar
      • Munich, Bavaria, Alemanha
        • Recrutamento
        • TUM Klinikum rechts der Isar
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

All cases registered for the hematology, orthopedics and sarcoma, and head and neck tumor boards of TUM University Hospital rechts der Isar during the study period. One case is one patient presentation on one board date.

Descrição

Inclusion Criteria:

  • Case registered for a session of a participating tumor board (hematology, orthopedics and sarcoma, head and neck) of TUM University Hospital rechts der Isar during the study period
  • Board registration and pre-board patient documents available before the session starts

Exclusion Criteria:

  • Case not discussed at the session, defined as no board report with a consensus decision for that date (deferred or withdrawn registrations)
  • Session without a shadow run of the system

Excluded cases are counted and reported by reason.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Hematology board

Consecutive cases presented at the hematology tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

Orthopedics and sarcoma board

Consecutive cases presented at the orthopedics and sarcoma tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

Head and neck board

Consecutive cases presented at the head and neck tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of Cases With Category Match Between System Draft and Board Decision
Prazo: Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)

Proportion of discussed cases in which the system draft and the board consensus decision fall into the same of seven decision categories (systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care, referral to the molecular tumor board). Overlap counts where either side carries a second category. Assessed by a pre-specified LLM judge (GLM-5.3-Flash, prompt V3, majority of three votes), pooled over the three boards. Tested for non-inferiority against the rate of the same system and judge on the retrospective reference sample of the same boards, margin 7.5 percentage points, one-sided alpha 0.025.

Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proportion of Cases Rated Concordant or Partially Concordant
Prazo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Category match with a substance score of at least 1 of 3 (concordant requires at least 2 of 3 on a primary-category match, 3 of 3 where only second categories overlap). Non-inferiority versus retrospective reference, margin 7.5 percentage points, tested after the primary outcome (hierarchical testing).

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases Rated Concordant, Partially Concordant and Not Concordant
Prazo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Proportion of cases rated concordant, partially concordant and not concordant by the LLM judge.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match per Board
Prazo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Category match and concordant or partially concordant per board, with 95% confidence intervals, descriptive.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Discordant Cases by Direction of Disagreement
Prazo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Among cases without category match, proportion in which the draft is more conservative, more aggressive or a different modality than the board decision.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match as Rated by Clinicians
Prazo: Within 3 months after the board session

In 30 to 50 cases per board, agreement between draft and board decision as rated by physicians who did not attend the session, and agreement between judge and clinicians on category match (percentage agreement, Cohen's kappa).

Within 3 months after the board session
Proportion of Citations Verified Word for Word Against Their Source
Prazo: At draft generation, before the board session

Proportion of citations per case that verify word for word against their source, and proportion of cases in which every citation verifies.

At draft generation, before the board session
Proportion of Cases With a Draft Completed Before the Board Session
Prazo: At draft generation, before the board session

Proportion of cases with a draft completed before the session starts, and generation time per case in minutes.

At draft generation, before the board session

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Number of Clinical Trials Shortlisted per Case by the Trial-Matching Engine
Prazo: At draft generation, before the board session

Number of trials shortlisted per case, proportion recruiting on the board date, rule-based error rate (wrong disease, line of therapy, setting or status) and clinician screening verdicts where given.

At draft generation, before the board session

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Lisa Adams, MD, Technical University of Munich
  • Investigador principal: Krischan Braitsch, MD, Technical University of Munich

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

9 de novembro de 2026

Conclusão Primária (Estimado)

31 de janeiro de 2027

Conclusão do estudo (Estimado)

30 de abril de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ONKOBOT-SHADOW-01
  • KK6050201BM5 (Número de outro subsídio/financiamento: Central Innovation Programme for SMEs (ZIM), German Federal Ministry for Economic Affairs)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data are routine clinical records that may not leave the hospital under the ethics approval and data protection concept. Aggregate results and the analysis code will be published.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .